Suramin disrupts insulin-like growth factor-II (IGF-II) mediated autocrine growth in human SH-SY5Y neuroblastoma cells

Brain Research

Volumn 744, Issue 2, 1997, Pages 199-206

  Sullivan, Kelli A ^a   Bhumsoo, Kim ^a   Buzdon, Molly ^b   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

autocrine; IGF II; neuroblastoma; SH SY5Y; suramin

Indexed keywords

SOMATOMEDIN; SURAMIN;

ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AUTOCRINE MOTILITY FACTOR; BRAIN NEOPLASMS; CELL DIVISION; HUMANS; INSULIN-LIKE GROWTH FACTOR II; NEUROBLASTOMA; SURAMIN; TUMOR CELLS, CULTURED;

EID: 0343036236     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)01078-5     Document Type: Article

References (62)

1. Bell, G.I., Merryweather, J.P., Sanchez-Pescador, R., et al., Sequence of a cDNA clone encoding human preproinsulin-like growth factor II, Nature, 310 (1984) 775-777.
2. Berns, E.M.J.J., Schuurmans, A.L.G., Bolt, J., Lamb, D.J., Foekens, J.A. and Mulder, E., Antiproliferative effects of suramin on androgen responsive tumour cells, Eur. J. Cancer, 26 (1990) 470-474.
3. Betsholtz, C., Johnsson, A., Heldin, C.-H. and Westermark, B., Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin, Proc. Natl. Acad. Sci. USA, 83 (1994) 6440-6444.
4. Braddock, P.S., Hu, D.-E., Fan, T.-P.D., Stratford, I.J., Harris, A.L. and Bicknell, R., A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions, Br. J. Cancer, 69 (1994) 890-898.
5. Broder, S., Collins, J.M., Markham, P.D., et al., Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo, Lancet, 2 (1985) 627-630.
6. Burch, T.A. and Ashburn, L.L., Experimental therapy of onchocerciasis with suramin and hetrazan; Results of a three-year study, Am. J. Trop. Med. Hygiene, 31 (1951) 617-623.
7. Chomczynski, P. and Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal. Biochem., 162 (1987) 156-159.
8. Coffey, R.J., Jr., Leof, E.B., Shipley, G.D. and Moses, H.L., Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells, J. Cell. Physiol., 132 (1987) 143-148.
9. Collins, J.M., Klecker, R.W., Yarchoan, R., et al., Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection, J. Clin. Pharmacol., 26 (1986) 22-26.
10. Darzynkiewicz, Z., Bruno, S., DelBino, G., et al., Features of apoptotic cells measured by flow cytometry, Cytometry, 13 (1992) 795-808.
11. De Angeli, S., Fandella, A., Conconi, M.T., Anselmo, G. and Parnigotto, P.P., Growth, morphology and morphometry of human hypertrophic prostate cells treated with suramin in vitro, Prostate, 25 (1994) 117-124.
12. DeClercq, E., Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses, Cancer Lett., 8 (1979) 9-22.
13. DiCicco-Bloom, E. and Black, I.B., Insulin growth factors regulate the mitotic cycle in cultured rat sympathetic neuroblasts, Proc. Natl. Acad. Sci. USA, 85 (1988) 4066-4070.
14. Falcone, A., Danesi, R., Zaccaro, L., et al., Synergistic antiproliferative activity of suramin and α 2A-interferon against human colorectal adenocarcinoma cell lines: In vitro studies, Eur. J. Cancer Part A, 30A (1994) 516-520.
15. Favoni, R.E., Ravera, F., Pirani, P., Ardizzoni, A., Noonan, D. and De Cupis, A., Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines, Eur. J. Pharmacol., 264 (1994) 199-206.
16. Feldman, E.L. and Randolph, A.E., Mannose 6-phosphate potentiates insulin-like growth factor II effects in cultured human neuroblastoma cells, Brain. Res., 562 (1991) 111-116.
17. Foekens, J.A., Sieuwerts, A.M., Stuurman-Smeets, E.M.J., Dorssers, L.C.J., Berns, E.M.J.J. and Klijn, J.G.M., Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro, Int. J. Cancer, 51 (1992) 439-444.
18. Foekens, J.A., Sieuwerts, A.M., Stuurman-Smeets, E.M.J., Peters, H.A. and Klijn, J.G.M., Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro, Br. J. Cancer, 67 (1993) 232-236.
19. Forsythe, I.D., Lambert, D.G., Nahorski, S.R. and Linsdell, P., Elevation of cytosolic calcium by cholinoceptor agonists in SH-SY5Y human neuroblastoma cells: estimation of the contribution of voltage-dependent currents, Br. J. Pharmacol., 107 (1992) 207-214.
20. Gill, J.S., Connolly, D.C., McManus, M.J., Maihle, N.J. and Windebank, A.J., Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons, J. Neurochem., 66 (1996) 963-972.
21. Gill, J.S., Hobday, K.L. and Windebank, A.J., Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures, Exp. Neurol., 133 (1995) 113-124.
22. Guo, X.-J., Fantini, J., Roubin, R., Marvaldi, J. and Rougon, G., Evaluation of the effect of suramin on neuronal cell growth and N-CAM expression, Cancer Res., 30 (1990) 5164-5170.
23. Hansen, M.B., Nielsen, S.E. and Berg, K., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods, 119 (1989) 203-210.
24. Huang, S.S. and Huang, J.S., Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin, J. Biol. Chem., 263 (1988) 12608-12618.
25. Jalonen, T. and Akerman, K.E.O., Single transient potassium channels in human neuroblastoma cells induced to differentiate in vitro, Neurosci. Lett., 86 (1988) 99-104.
26. Jindal, H.K., Anderson, C.W., Davis, R.G. and Vishwanatha, J.K., Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases, Cancer Res., 50 (1990) 7754-7757.
27. Jodrell, D.I., Reyno, L.M., Sridhara, R., et al., Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer, J. Clin. Oncol., 12 (1994) 166-175.
28. Kloen, P., Jennings, C.L., Gebhardt, M.C., Springfield, D.S. and Mankin, H.J., Suramin inhibits growth and transforming growth factor-βl (TGF-βl) binding in osteosarcoma cell lines, Eur. J. Cancer Part A, 30A (1994) 678-682.
29. Kopp, R. and Pfeiffer, A., Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells, Cancer Res., 50 (1990) 6490-6496.
30. Kraft, A., Reid, L.M. and Zvibel, I., Suramin inhibits growth and yet promotes insulin-like growth factor II expression in HepG2 cells, Cancer Res., 53 (1993) 652-657.
31. La Rocca, R.V., Cooper, M.R., Danesi, R., Stein, C.A. and Myers, C.E., Suramin therapy for malignant thymoma: A case report, Eur. J. Cancer Part A, 30A (1994) 718-719.
32. LaRocca, R.V., Meer, J., Gilliatt, R.W., et al., Suramin-induced polyneuropathy, Neurology, 40 (1990) 954-960.
33. Leventhal, P.S., Randolph, A.E., Vesbit, T.E., Schenone, A., Windebank, A.J. and Feldman, E.L., Insulin-like growth factor-II as a paracrine growth factor in human neuroblastoma cells, Exp. Cell. Res., 221 (1995) 179-186.
34. Lindman, H., Taube, A. and Bergh, J.C.S., Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein, Anticancer Res., 14 (1994) 363-366.
35. Martin, D.M., Carlson, R.O. and Feldman, E.L., Interferon-g inhibits DNA synthesis and insulin-like growth factor-II expression in human neuroblastoma cells, J. Neurosci. Res., 34 (1993) 489-501.
36. Martin, D.M. and Feldman, E.L., Regulation of insulin-like growth factor-II expression and its role in autocrine growth of human neuroblastoma cells, J. Cell Physiol., 155 (1993) 290-300.
37. Martin, D.M., Singleton, J.R., Meghani, M.A. and Feldman, E.L., IGF receptor function and regulation in autocrine human neuroblastoma cell growth, Regul. Peptides, 48 (1993) 225-232.
38. Martin, D.M., Yee, D., Carlson, R.O. and Feldman, E.L., Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cells, Mol. Brain Res., 15 (1992) 241-246.
39. Matthews, C.C. and Feldman, E.L., Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death, J. Cell Physiol., 166 (1996) 323-331.
40. McMorris, F.A. and Dubois-Dalcq, M., Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro, J. Neurosci. Res., 21 (1988) 199-209.
41. Meghani, M.A., Martin, D.M., Singleton, J.R. and Feldman, E.L., Effects of serum and insulin-like growth factors on human neuroblastoma cell growth, Regul. Peptides, 48 (1993) 217-224.
42. Mills, G.B., Zhang, N., May, C., Hill, M. and Chung, A., Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression, Cancer Res., 50 (1990) 3036-3042.
43. Minniti, C.P., Maggi, M. and Helman, L.J., Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop, Cancer Res., 52 (1992) 1830-1835.
44. Morocz, I.A., Lauber, B., Schmitter, D. and Stahel, R.A., In vitro effect of suramin on lung tumour cells, Eur. J. Cancer, 29A (1993) 245-247.
45. Motzer, R.J., Nanus, D.M., O'Moore, P., et al., Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression, Cancer Res., 52 (1992) 5775-5779.
46. Olson, J.J., Polk, D.M. and Reisner, A., The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma, Neurosurgery, 34 (1994) 297-308.
47. Oltvai, Z.N., Milliman, C.L. and Korsmeyer, S.J., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death, Cell, 74 (1993) 609-619.
48. Ono, K., Nakane, H. and Fukushima, M., Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin, Eur. J. Biochem., 172 (1995) 349-353.
49. Pahlman, S., Mamaeva, S., Meyerson, G., et al., Human neuroblas-toma cells in culture: a model for neuronal cell differentiation and function, Acta Physiol. Scand. (Suppl.), 592 (1990) 25-37.
50. Pollak, M. and Richard, M., Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells, J. Natl. Cancer Inst., 82 (1990) 1349-1352.
51. Prager, D., Yamasaki, H., Weber, M.M. and Melmed, S., Role of the insulin-like growth factors in regulating neuroendocrine function, Neurobiol. Aging, 15 (1994) 569-572.
52. Ravera, F., Miglietta, L., Pirani, P., Ferrini, S. and Favoni, R.E., Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: Potentially related events, Eur. J. Cancer Part A, 29A (1993) 225-230.
53. Rees, S., Membranous neuronal and neuroglial inclusions produced by intracerebral injection of suramin, J. Neurol. Sci., 36 (1978) 97-109.
54. Reuveny, E. and Narahashi, T., Two types of high voltage-activated calcium channels in SH-SY5Y human neuroblastoma cells, Brain Res., 603 (1993) 64-73.
55. Russell, J.W., Windebank, A.J. and Podratz, J.L., Role of nerve growth factor in suramin neurotoxicity studied in vitro, Ann. Neurol., 36 (1994) 221-228.
56. Stein, C.A., LaRocca, R.V., Thomas, R., McAtee, N. and Myers, C.E., Suramin: An anticancer drug with a unique mechanism of action, J. Clin. Oncol., 7 (1989) 499-508.
57. Sumantran, V.N. and Feldman, E.L., Insulin-like growth factor I regulates c-myc and GAP-43 messenger ribonucleic acid expression in SH-SY5Y human neuroblastoma cells, Endocrinology, 132 (1993) 2017-2023.
58. Takano, S., Gately, S., Neville, M.E., et al., Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator, Cancer Res., 54 (1994) 2654-2660.
59. 125I-insulin-like growth factor-I binding to human meningiomas and on proliferation of meningioma cells, J. Neurosurg., 80 (1994) 502-509.
60. 125I-epidermal growth factor binding to human meningiomas, Cell Mol. Neurobiol., 13 (1993) 665-675.
61. Vignon, F., Prebois, C. and Rochefort, H., Inhibition of breast cancer growth by suramin, J. Natl. Cancer Inst., 84 (1992) 38-42.
62. Voogd, T.E., Vansterkenburg, E.L.M., Wilting, J. and Janssen, L.H.M., Recent research on the biological activity of suramin, Pharmacol. Rev., 45 (1993) 177-203.